Mucosal IgA responses in influenza virus infections; thoughts for vaccine design
- PMID: 22835738
- DOI: 10.1016/j.vaccine.2012.04.109
Mucosal IgA responses in influenza virus infections; thoughts for vaccine design
Abstract
The current challenge in influenza vaccine design is to induce long-lasting protection not only against the vaccine strain, but also against drifted (point mutations in the surface antigens HA or NA) and even shifted (exchange of genome segments) strains. Several immune mediators that can induce cross-protection have been described, such as CD4 T-cells, CD8 T-cells and antibodies, including IgA. However, most vaccines are now administered intramuscularly or subcutaneously and subsequently relatively little is known on the role of local, mucosal responses. Since local IgA responses have been shown to play an important role in responses to natural infection, and IgA responses in mice were shown to also be involved in cross-protection, the research on mucosal influenza vaccines is currently expanding. However, the functioning of the mucosal immune system, especially in the respiratory tract, is just beginning to be revealed. Here, the current knowledge on the induction of IgA, the role of influenza specific IgA producing B-cells in anti-influenza immunity as well as the role of humoral memory responses induced upon vaccination will be reviewed.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Defense mechanisms against influenza virus infection in the respiratory tract mucosa.Jpn J Infect Dis. 2004 Dec;57(6):236-47. Jpn J Infect Dis. 2004. PMID: 15623947 Review.
-
Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.Vaccine. 2012 Jul 6;30(32):4884-91. doi: 10.1016/j.vaccine.2012.04.032. Epub 2012 Apr 23. Vaccine. 2012. PMID: 22537989
-
Vaccine-specific antibody secreting cells are a robust early marker of LAIV-induced B-cell response in ferrets.Vaccine. 2012 Jan 5;30(2):237-46. doi: 10.1016/j.vaccine.2011.11.001. Epub 2011 Nov 12. Vaccine. 2012. PMID: 22080173
-
Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.J Clin Virol. 2004 Dec;31 Suppl 1:S99-106. doi: 10.1016/j.jcv.2004.09.013. J Clin Virol. 2004. PMID: 15567101
-
Keeping the memory of influenza viruses.Pathol Biol (Paris). 2010 Apr;58(2):e79-86. doi: 10.1016/j.patbio.2010.01.010. Epub 2010 Mar 19. Pathol Biol (Paris). 2010. PMID: 20303671 Review.
Cited by
-
Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model.Vaccine. 2017 Jan 23;35(4):586-595. doi: 10.1016/j.vaccine.2016.12.025. Epub 2016 Dec 23. Vaccine. 2017. PMID: 28024958 Free PMC article.
-
Calboxyvinyl polymer adjuvant enhances respiratory iga responses through mucosal and systemic administration.NPJ Vaccines. 2025 Feb 11;10(1):28. doi: 10.1038/s41541-025-01086-0. NPJ Vaccines. 2025. PMID: 39934182 Free PMC article.
-
A Dual Adjuvant System for Intranasal Boosting of Local and Systemic Immunity for Influenza Vaccination.Vaccines (Basel). 2022 Oct 11;10(10):1694. doi: 10.3390/vaccines10101694. Vaccines (Basel). 2022. PMID: 36298559 Free PMC article.
-
Full inactivation of human influenza virus by high hydrostatic pressure preserves virus structure and membrane fusion while conferring protection to mice against infection.PLoS One. 2013 Nov 25;8(11):e80785. doi: 10.1371/journal.pone.0080785. eCollection 2013. PLoS One. 2013. PMID: 24282553 Free PMC article.
-
Efficacy of Heterologous Prime-Boost Vaccination with H3N2 Influenza Viruses in Pre-Immune Individuals: Studies in the Pig Model.Viruses. 2020 Sep 1;12(9):968. doi: 10.3390/v12090968. Viruses. 2020. PMID: 32882956 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous